Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
95.24B
Market cap95.24B
Price-Earnings ratio
20.38
Price-Earnings ratio20.38
Dividend yield
0.40%
Dividend yield0.40%
Average volume
892.58K
Average volume892.58K
High today
$948.42
High today$948.42
Low today
$916.66
Low today$916.66
Open price
$935.24
Open price$935.24
Volume
856.83K
Volume856.83K
52 Week high
$991.73
52 Week high$991.73
52 Week low
$591.52
52 Week low$591.52

Stock Snapshot

Regeneron(REGN) stock is priced at $920.59, giving the company a market capitalization of 95.24B. It carries a P/E multiple of 20.38 and pays a dividend yield of 0.40%.

On 2026-11-21, Regeneron(REGN) stock moved within a range of $916.66 to $948.42. With shares now at $920.59, the stock is trading +0.4% above its intraday low and -2.9% below the session's peak.

Trading activity shows a volume of 856.83K, compared to an average daily volume of 892.58K.

The stock's 52-week range extends from a low of $591.52 to a high of $991.73.

The stock's 52-week range extends from a low of $591.52 to a high of $991.73.

REGN News

Investor's Business Daily 8h
Visa And Regeneron Are Thriving Despite The Market Meltdown - Investor's Business Daily

...

Visa And Regeneron Are Thriving Despite The Market Meltdown - Investor's Business Daily
Benzinga 2d
Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot

On Wednesday, the U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) Livsayis (cemdisiran) for generalized myasthenia gra...

Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
TipRanks 2d
Regeneron’s Buy Rating Reaffirmed on Livtayo Approval and Pipeline Strength; Price Target Unchanged at $1,050

Evan Seigerman, an analyst from BMO Capital, maintained the Buy rating on Regeneron. The associated price target remains the same with $1,050.00. Evan Seigerma...

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More REGN News

TipRanks 2d
Alnylam announces FDA approved Livsayis for treatment of gMG

Alnylam (ALNY) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved Livsayis, an Alnylam-discovered RNAi therapeutic that was...

Seeking Alpha 2d
Regeneron, Alnylam win FDA nod for myasthenia gravis therapy

Regeneron Pharmaceuticals (REGN) has received U.S. approval for Livsayis (cemdisiran), an RNA therapeutic developed with Alnylam Pharmaceuticals (ALNY) as a tre...

Regeneron, Alnylam win FDA nod for myasthenia gravis therapy
TipRanks 2d
Regeneron announces new hematology portfolio data at ASH

Regeneron (REGN) announced new and updated data from its hematology portfolio and pipeline will be shared across 14 abstracts at the American Society of Hematol...

Simply Wall St 2d
FDA Approval Could Be A Big Moment For Regeneron Stock

Regeneron Pharmaceuticals received past FDA approval for Livsayis (cemdisiran) to treat anti acetylcholine receptor antibody positive generalized myasthenia gra...

FDA Approval Could Be A Big Moment For Regeneron Stock
Seeking Alpha 3d
CytomX to receive $5M from Regeneron for cancer drug milestone

CytomX Therapeutics (CTMX) announced it will receive a $5 million payment after reaching a preclinical milestone in its cancer drug development partnership with...

CytomX to receive $5M from Regeneron for cancer drug milestone
TipRanks 3d
CytomX Therapeutics triggers $5M milestone payment in Regeneron collaboration

CytomX Therapeutics (CTMX) announced the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron (REGN), trigger...

Seeking Alpha 4d
Regeneron wins EU nod for alternative Libtayo regimen

Regeneron wins EU nod for alternative Libtayo regimen Nov 17, 2026, 2:17 PM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock By : Dulan Lokuwithana, SA News Edit...

Regeneron wins EU nod for alternative Libtayo regimen

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.